| From: jmhollen | 4/6/2005 4:23:26 AM | | | | | | GenoMed Speaks Today at 1st Annual World Congress Leadership Summit on Disease Management and Chronic Care
Contact: Dr. David Moskowitz
GenoMed, Inc. tel. 314-983-9933 dwmoskowitz@genomed.com
April 5, 2005--GenoMed Inc.-- ("the Company" or "GenoMed") (National Quotation Bureau's Pink Sheets Symbol: GMED) a St. Louis, Missouri-based Next Generation Disease Management company, announced that its Chairman and CEO, Dr. David Moskowitz, has been invited to speak today at The 1st Annual World Congress Leadership Summit on Disease Management and Chronic Care.
This conference, held outside Washington, DC (http://www.worldcongress.com/wcls/ccd/index.cfm) presents the nation's best practices and thought leaders in implementing successful disease management programs that produce positive clinical and financial outcomes. The conference agenda was designed to address the market demands from employers and public purchasers as well as the leading edge programs offered by health care insurers and providers. The agenda highlights legislative trends that impact the adoption and scope of disease management programs including updates from the Centers for Medicaid and Medicare (CMS) on its Chronic Care Improvement Program.
Said Dr. Moskowitz, GenoMed's CEO and Chief Medical Officer, "We've been invited to this inaugural conference because our business model consists of using genomics to improve public health, and we've been uniquely successful at it so far for diabetes, hypertension, and emphysema, which together affect over 85 million Americans."
Continued Dr. Moskowitz, "GenoMed's business model is ideal for today's political climate. It is tailor-made for Health Savings Accounts (HSA's) and Consumer-Directed Health Care (CDHC). In addition to educating health plans about its Next Generation DM(tm) services, GenoMed is also encouraging patients who control their own Health Savings Account or who can afford $67 a month out-of-pocket to sign up themselves for GenoMed's services."
About GenoMed
GenoMed has found what it believes to be the major gene for aging, and has already been able to prevent kidney failure due to diabetes and hypertension in whites, blacks and Hispanics; dramatically delay the progression of terminal emphysema; and begin to see treatment successes for autoimmune diseases, West Nile virus encephalitis, and cancer. GenoMed has recently found several thousand genes for the top six solid cancers--breast, colon, lung, ovarian, pancreatic, and prostate--and expects to have new diagnostic tools ready for clincal trials soon, with new cancer chemotherapy to follow.
|
| | GMED - GenoMed Inc. | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| From: jmhollen | 4/20/2005 11:42:42 AM | | | | | | GenoMed Completes First Version of Healthchip(r) for Cancer Prediction
Contact: David Moskowitz MD tel. 314-983-9933 GenoMed, Inc.
ST. LOUIS, April 20, 2005 -- GenoMed, Inc. (Pink Sheets GMED) a Next Generation Disease Management company, said today that it has constructed a Healthchip® which may serve as an early warning system for the top six common cancers in whites: breast, colon, lung, ovarian, pancreatic, and prostate.
GenoMed's Healthchip® is made up of many single nucleotide polymorphisms (SNPs). In internal testing, the Healthchip® correctly identified the type of cancer in 85% of cases. None of the normals were misdiagnosed. More testing is required to confirm these results.
The well known breast cancer genes, BRCA1 and BRCA2, account for only 5% of breast cancers in white women. GenoMed's SNPs may pick up the remaining 95% of sporadic breast cancer cases in white women, i.e. in women without a strong family history of breast cancer.
Said Dr. David Moskowitz, GenoMed's chairman and chief executive officer, "It's important for any screening test to have as few false positives as possible. GenoMed's Healthchip® currently has none."
The test for mutations in the BRCA1 and BRCA2 genes costs about $1,200, has been available for about a decade, and has been reimbursed by a handful of insurance plans for the past few years. GenoMed's test is currently available for research purposes only, and is not yet reimbursable by any health plan. Please contact Dr. Moskowitz at dwmoskowitz@genomed.com to inquire about GenoMed's testing program.
. |
| | GMED - GenoMed Inc. | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| From: jmhollen | 5/5/2005 2:25:49 PM | | | | | | GenoMed CEO Invited to Speak at Harvard Medical School 25th Class Symposium
Contact: David Moskowitz MD GenoMed, Inc. dwmoskowitz@genomed.com tel. 314-983-9933
ST. LOUIS--(May 5, 2005)--GenoMed Inc. ("the Company" or "GenoMed") (National Quotation Bureau's Pink Sheets Symbol GMED) announced today that its CEO, David Moskowitz MD, has been invited to speak on Clinical Genomics at the 25th Class Symposium at Harvard Medical School on June 9, 2005 (http://134.174.17.106/alumni/program-05.pdf
Said Dr. Moskowitz, "It's a tremendous honor to be selected to speak at our 25th medical class reunion. Since publishing three years ago that angiotensin I-converting enzyme ('ACE') might be the aging gene, I've been trying hard to get the word out. Last week at 'World DNA and Genome Day' in Dalian, China, the reception was quite enthusiastic. Speaking at Harvard next month should be equally productive. I've already gotten inquiries from Harvard Medical School alumni who've seen the Class Day program. The point of my talk will be that all physicians should be practicing clinical genomics already."
Added Dr. Moskowitz, "GenoMed's primary goal right now is to educate the 80 million American Baby Boomers and their physicians, not to mention the rest of the world, that medicine has already been revolutionized. Unfortunately, an entire cohort of kidney patients is just now going on dialysis in the U.S. because their physicians didn't hear about our published results three years ago. If we'd gotten to these patients then, we could have kept them off the kidney machine now. Getting the word out to patients and their physicians in time is absolutely critical. Disease doesn't wait."
About GenoMed
GenoMed, Inc. is a Next Generation DM(TM) company whose mission is to improve patient outcomes by identifying the molecular pathways that cause disease. Disease Management (DM) is the only business in healthcare which profits by lowering healthcare costs. GenoMed uses clinical genomics to keep patients healthier and out of the hospital. A St. Louis Business Journal article (http://www.stlouis.bizjournals.com/stlouis/stories/2002/05/13/story8.html) first reported that GenoMed applied for patents based on its finding that the ACE gene is associated with many common diseases.
. |
| | GMED - GenoMed Inc. | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
| To: jmhollen who wrote (257) | 5/7/2005 8:41:25 AM | | From: Tadsamillionaire | | | | Dr M's Thoughts about the roomers of a Gmed buyout:
Dear ,
There's no way we'd sell out cheaply, not when each wild
card patent would be worth two years of a $3 billion a year drug. We may have the makings of 20 or 30 of these wild card patents. Do the math: $3B/yr x 2 yr/wild-card x 30 wild-card patents = $180 B.
We'd also have to retain full operational control over our Next Generation DM(tm) activities in any acquisition.
So if we get acquired, it won't be cheap. My goal remains to be huge ourselves. I just wanted people to have
some idea of the magnitude of what we might be sitting on, since (a) preventing kidney dialysis, (b) significantly delaying emphysema, (c) finding the aging gene for all vertebrate species, (d) being able to predict which Caucasians will get which of the top six solid cancers, (e)
having a potential broad-spectrum anti-viral treatment, (f) having a SNPnet which can efficiently find predisposition genes for all cancers in all ethnic groups, and (g) inventing a business model that finally makes preventive medicine profitable, have evidently not been enough to be
valued by the market at more than 6 cents a share.
All I can say is, talk about a tough audience! Enron, etc. did more than just destroy consumer confidence. Those boys destroyed trust in any company. Then again, maybe our problem is just lack of publicity. I continue to think
that 80 million Baby Boomers might appreciate knowing about (c), at the very least. Unless they still think they're going to live forever, as we
did in 1968.
Yours sincerely,
Dave Moskowitz MD
ragingbull.lycos.com |
| | GMED - GenoMed Inc. | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
| To: jmhollen who wrote (259) | 5/26/2005 8:18:07 PM | | From: Tadsamillionaire | | | | Growing concern over a persistent epidemic of bird flu across Asia is leading to urgent calls from international scientists to prepare for a global flu pandemic that could strike, by some estimates, 20% of the world's population. In a collection of articles published Thursday in the journal Nature, scientists sketch out a scenario in which a strain of bird flu, which usually would not be dangerous to people, adapts to become highly contagious and deadly to humans.
news.yahoo.com |
| | GMED - GenoMed Inc. | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| From: Tadsamillionaire | 5/26/2005 8:21:00 PM | | | | | | Avian influenza – cumulative number of cases – update 18
19 May 2005
WHO is updating its table showing cumulative numbers of human cases of H5N1 avian influenza broken down according to phases in the outbreak, which began in December 2003. [Cumulative Number of Confirmed Human Cases of Avian Influenza A/(H5N1) Reported to WHO]. Numbers for Viet Nam, where the vast majority of recent cases have occurred, have been amended in line with case counts provided by the Ministry of Health during late April and May. Since the third wave of infection began in Viet Nam in mid-December 2004, 49 cases have been reported. Of these cases, 17 were fatal. The most recent case was reported to the ministry on 17 April.
WHO has asked the Ministry of Health in Viet Nam to supplement the numbers with data on individual cases. Rapid field investigation of new cases, especially when these occur in clusters, remains essential to assess possible changes in transmission patterns that could indicate improved pandemic potential of the virus.
Since January 2004, when human cases of H5N1 avian influenza were first reported in the current outbreak, 97 cases and 53 deaths have been reported in Viet Nam, Thailand and Cambodia. Viet Nam, with 76 cases and 37 deaths, has been the most severely affected country, followed by Thailand, with 17 cases and 12 deaths, and Cambodia, with 4 cases and 4 deaths.
who.int
U.S. unprepared against new flu -experts The United States still has no licensed vaccine to prevent avian flu and has nowhere near enough drugs to treat the sick if there is an epidemic, experts told Congress on Thursday.
Hospitals have too little capacity to deal with the huge numbers of people who would become sick and the U.S. Health and Human Services Department does not have a plan for dealing with an epidemic, the experts said.
"Although many levels of government are paying increased attention to the problem, the United States remains woefully unprepared for an influenza pandemic that could kill millions of Americans," said Dr. Andrew Pavia, chairman of the Infectious Disease Society of America's Pandemic Influenza Task Force.
"Clearly, we need a much larger supply of drugs and vaccine to control a flu pandemic. We need to build up U.S. manufacturing capacity so that we are not dependent on other countries to meet our needs," Pavia said in remarks prepared for a hearing of the health subcommittee of the House of Representatives' Energy and Commerce Committee.
Dr. Julie Gerberding, director of the U.S. Centers for Disease Control and Prevention, said the government was working hard to address the threat.
"CDC's influenza budget is $197 million ... a lot larger than just a few years ago," Gerberding said. "We have a lot of work to do, and that work needs to be a priority."
The H5N1 strain of avian flu has killed 37 people in Vietnam, 12 in Thailand and four in Cambodia.
It could sicken up to 20 percent of the world's population if it acquires the ability to pass easily among people, says influenza expert Dr. Albert Osterhaus of the Erasmus Medical Center in Rotterdam, Netherlands.
A pandemic could send 30 million people to the hospital and a quarter of them could die, Osterhaus and colleagues predicted in articles in Thursday's issue of the journal Nature.
Influenza causes epidemics annually and kills 36,000 Americans in a normal season. Different strains emerge almost annually, and a new one can kill many more if it is one that has not affected people in recent years.
A brand-new strain, such as H5N1, could be devastating.
"The U.S. population has no immunity and therefore no protection against this deadly virus," Pavia said.
He recommended that the United States stockpile a larger supply of antiviral drugs, especially oseltamivir, made by Switzerland's Roche under the brand name Tamiflu. Avian influenza resists older antiviral drugs, like amantadine and rimantadine, but Tamiflu can help make an infection less severe.
Although Roche has quadrupled its production capacity for Tamiflu, experts believe global stockpiles will be too small for a pandemic. The current stockpile would treat less than 2 percent of the U.S. population. Pavia's group recommends having enough on hand to treat 50 percent.
The U.S. government has also contracted with Sanofi-Aventis and Chiron Corp. to make H5N1 flu vaccines, but the contracts provide for only 2 million doses and the vaccines are still experimental.
The U.S. Government Accountability Office also criticized the U.S. lack of preparation.
Marcia Crosse, Director of Health Care for the GAO, said in prepared testimony that the United States needs to address regulatory, privacy, and procedural issues surrounding measures to control the spread of disease, especially across borders.
news.yahoo.com
|
| | GMED - GenoMed Inc. | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| From: Tadsamillionaire | 5/26/2005 8:25:13 PM | | | | | | Flu pandemic warnings escalate
By Anita Manning, USA TODAY
Growing concern over a persistent epidemic of bird flu across Asia is leading to urgent calls from international scientists to prepare for a global flu pandemic that could strike, by some estimates, 20% of the world's population. usatoday.com
Subject 52075 |
| | GMED - GenoMed Inc. | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| From: Tadsamillionaire | 5/26/2005 8:31:11 PM | | | | | | Avian flu special: Avian flu: Are we ready?
Peter Aldhous1 and Sarah Tomlin2
Peter Aldhous, chief news & features editor.
Sarah Tomlin, commentary editor.
Trouble is brewing in the East. A highly pathogenic strain of avian influenza is endemic in southeast Asia. Many millions of chickens have been culled, but there is a persistent reservoir in domesticated ducks and wild birds. The H5N1 virus isn't going to go away. And each time it emerges, people can be infected.
H5N1 first reared its head in Hong Kong and southern China in 1997, killing six. Since late 2003, it has led to the deaths of more than 50 people in Vietnam, Thailand and Cambodia.
The stage is set for the emergence of a fresh human influenza pandemic. These occur when a virus to which most people have no immunity, usually an avian strain, acquires the ability to transmit readily from person to person. H5N1 hasn't yet gained that ability — and hopefully, it will not.
But if it does, the virus could spread across the globe within months. The consequences are difficult to predict. We're unlikely to be as lucky as in 1968, when the relatively mild H3N2 virus killed some 750,000 people worldwide. But the real nightmare scenario is a re-run of the H1N1 flu pandemic of 1918, which left as many as 40 million dead. Standards of health care have improved a lot since then, which will help. But if a pandemic strain were to retain H5N1's current extreme pathogenicity, a similar toll can't be ruled out.
This week, Nature devotes its News Feature and Commentary pages to a detailed consideration of the risks posed by avian flu, and how well we are prepared to deal with it. In the pages that follow, our reporters examine nations' capacity to produce a vaccine against a pandemic strain, and the adequacy of global stockpiles of antiviral drugs. They do not paint an encouraging picture.
Repeated warnings about the international community's failure to respond to the pandemic threat have fallen on deaf ears. So in our opening News Feature, we use the benefit of fictional hindsight to throw the issues into starker relief, describing a future pandemic through the weblog of a journalist in the thick of things. This is fiction, but not fantasy — the storyline was drawn up in consultation with those who could soon be dealing with the situation for real.
In our extended Commentary section, starting on page 415, experts who are grappling with the issues tackle some hard questions. Which nations are ready, and which are not? David Ho asks if China is in a better position to cope with new microbial threats since the 2003 SARS outbreak. And Anthony Fauci outlines what US researchers are doing to develop vaccines and drugs.
Asian countries are the most immediately vulnerable. Robert Webster and Diane Hulse address the possibility of controlling flu outbreaks in these nations at source, pointing to two examples of successful intervention to wipe out the disease in poultry — in Hong Kong in 1997 and more recently in Thailand. Joining up the dots between animal and human health is also the concern of Albert Osterhaus and his colleagues. They propose a permanent global flu task force to strengthen coordination among agencies on the ground.
If we are fortunate, we may still have the time to take these messages on board. As Michael Osterholm warns in his Commentary, a flu pandemic could bring human tragedy and a global economic catastrophe. Let's hope world leaders heed the warnings.
nature.com |
| | GMED - GenoMed Inc. | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| From: jmhollen | 6/7/2005 9:33:14 AM | | | | | | GenoMed Announces 3rd Year of its West Nile Virus Trial; Now Part of BioShield II
Contact: Paula Hempen, PhD GenoMed, Inc. tel. 314-983-9933
David Moskowitz MD GenoMed, Inc. dwmoskowitz@genomed.com
ST. LOUIS--June 7, 2005--GenoMed Inc.-- ("the Company" or "GenoMed") (National Quotation Bureau's Pink Sheets Symbol: GMED) a St. Louis, Missouri-based Next Generation Disease Management company, announced today that it will be conducting a clinical trial to prevent and treat West Nile virus encephalitis for the third summer in a row. The Company's approach to viral diseases was recently included in BioShield II, the landmark anti-bioterrorism bill recently introduced in the U.S. Senate by Senators Joseph Lieberman (D-CT), Orrin Hatch (R-UT), and Sam Brownback (R-KS).
A part of the bill reads:
"CHAPTER 5; REPORT AND ADMINISTRATION. SEC. 2151. REPORT TO CONGRESS. Not later than 180 days after the date of enactment of this Act, the Director of the Centers for Disease Control and Prevention, in consultation with the Assistant Secretary for Medical Readiness and Response of the Department of Homeland Security and the Director of the National Institute for Allergy and Infectious Disease of the National Institutes of Health, shall submit a report to Congress that describes alternatives to traditional vaccines and anti-viral therapeutics for viral diseases, including negative immunomodulation compounds that partially suppress a macrophage-dependent innate immune response of an individual to viral pathogens, in order to decrease morbidity and mortality from an excessive immune response."
This language exactly describes GenoMed's patent-pending method to gently suppress the innate immune response in order to treat most viral diseases in the general population.
Said Dr. Moskowitz, GenoMed's CEO and Chief Medical Officer, "Our record in West Nile virus currently stands at 11-3. For best results, we know to use our treatment in patients who aren't immunocompromised, and to begin treatment early."
Physicians in Utah, and Stanislaus County in California, are currently studying GenoMed's WNV protocol for use in their residents.
GenoMed's protocol was also used last summer by bird rescuers, with a 50% success rate. A second trial is planned again for this summer. Owls, hawks, and eagles have been saved using GenoMed's protocol, but so far no crows. This year's goal is to try to save crows, too.
"Horses should also benefit from our approach," Dr. Moskowitz added. "Veterinarians already use non-steroidal drugs to try to reduce the brain inflammation in horses, so our anti-inflammatory approach should make sense to them."
To enroll in GenoMed's trial, which uses already existing, safe medication present in every drug store, just go to www.genomed.com and click on the link for the West Nile virus trial.
About GenoMed
GenoMed has found what it believes to be the "master" disease gene, and has already been able to prevent kidney failure due to diabetes and hypertension in whites, blacks and Hispanics; dramatically delay the progression of terminal emphysema; and begin to see success in treating autoimmune diseases, West Nile virus encephalitis, and cancer. GenoMed has recently found several thousand genes for the top six solid cancers in Caucasians--breast, colon, lung, ovarian, pancreatic, and prostate--and is currently offering its Healthchip(r) for early diagnosis of cancer on a research basis.
|
| | GMED - GenoMed Inc. | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| |
